CTI BIOPHARMA CORP: 10-Q filed 2017-05-03
What CTI BIOPHARMA CORP reported in its quarterly report filed 2017-05-03 (fiscal Q1 2017): 36 published measures, 74 facts as tagged in accession 0000891293-17-000054.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2017-05-03
- Fiscal period
- fiscal Q1 2017
- Accession
- 0000891293-17-000054 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CTI BIOPHARMA CORP filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 44,660,000 | USD | |
| At 2016-12-31 | 63,843,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 55,033,000 | USD | |
| At 2016-12-31 | 56,086,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | -4,704,000 | USD | |
| At 2016-12-31 | 13,319,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 33,283,000 | USD | |
| At 2016-12-31 | 44,002,000 | USD | |
| At 2016-03-31 | 104,641,000 | USD | |
| At 2015-12-31 | 128,182,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | -19,828,000 | USD | 90 |
| 2016-01-01 to 2016-03-31 | 3,312,000 | USD | 91 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | 0 | USD | 90 |
| 2016-01-01 to 2016-03-31 | 29,000 | USD | 91 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | 754,000 | USD | 90 |
| 2016-01-01 to 2016-03-31 | 36,475,000 | USD | 91 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | -2,170,154,000 | USD | |
| At 2016-12-31 | -2,150,326,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | 28,045,000 | shares | 90 |
| 2016-01-01 to 2016-03-31 | 27,793,000 | shares | 91 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | 28,045,000 | shares | 90 |
| 2016-01-01 to 2016-03-31 | 27,816,000 | shares | 91 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | -0.71 | USD/shares | 90 |
| 2016-01-01 to 2016-03-31 | 0.12 | USD/shares | 91 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | -0.71 | USD/shares | 90 |
| 2016-01-01 to 2016-03-31 | 0.12 | USD/shares | 91 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 2,830,000 | USD | |
| At 2016-12-31 | 3,023,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | 1,799,000 | USD | 90 |
| 2016-01-01 to 2016-03-31 | 3,826,000 | USD | 91 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | -19,320,000 | USD | 90 |
| 2016-01-01 to 2016-03-31 | 4,127,000 | USD | 91 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 36,770,000 | USD | |
| At 2016-12-31 | 55,824,000 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | 534,000 | USD | 90 |
| 2016-01-01 to 2016-03-31 | 714,000 | USD | 91 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 41,874,000 | USD | |
| At 2016-12-31 | 40,646,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 11,878,000 | USD | |
| At 2016-12-31 | 7,227,000 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 311,000 | USD | |
| At 2016-12-31 | 378,000 | USD |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 1,502,000 | USD | |
| At 2016-12-31 | 1,525,000 | USD |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | 10,688,000 | USD | 90 |
| 2016-01-01 to 2016-03-31 | 11,312,000 | USD | 91 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 28,224,447 | shares | |
| At 2016-12-31 | 28,228,602 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | -6,611,000 | USD | |
| At 2016-12-31 | -6,655,000 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | -10,373,000 | USD | |
| At 2016-12-31 | 7,757,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 5,060,000 | USD | |
| At 2016-12-31 | 4,996,000 | USD |
Other noncurrent liabilities
Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 3,478,000 | USD | |
| At 2016-12-31 | 3,615,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 20,903,000 | USD | |
| At 2016-12-31 | 24,765,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 1,554,000 | USD | |
| At 2016-12-31 | 2,141,000 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | -19,935,000 | USD | 90 |
| 2016-01-01 to 2016-03-31 | 2,991,000 | USD | 91 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | -19,784,000 | USD | 90 |
| 2016-01-01 to 2016-03-31 | 3,939,000 | USD | 91 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | 0 | USD | 90 |
| 2016-01-01 to 2016-03-31 | -519,000 | USD | 91 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | -615,000 | USD | 90 |
| 2016-01-01 to 2016-03-31 | -1,136,000 | USD | 91 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | -73,000 | USD | 90 |
| 2016-01-01 to 2016-03-31 | 679,000 | USD | 91 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | -48,000 | USD | 90 |
| 2016-01-01 to 2016-03-31 | -68,000 | USD | 91 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | 4,635,000 | USD | 90 |
| 2016-01-01 to 2016-03-31 | 7,120,000 | USD | 91 |
Inspect the source
- Entity
- CTI BIOPHARMA CORP / CIK 0000891293
- Captured
- SEC response SHA-256
4ee4ccdafdc702cf7640160462fbdf4d50f1957e4319a255a21075530c4cb447
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000891293.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))